OUR SCIENCE

Antibody-Drug Conjugates

We are exploring next generation linker/payload technologies platform with the aim to develop "first-in-class/best-in-class" antibody-drug conjugates (ADCs) as monotheraphy and combination therapy with DDRi, targeted therapies or immune-checkpoint inhibitors

TARGETS UNDER INVESTIGATION

Abbreviations:
CEACAM5, carcinoembryonic antigen-related cell adhesion molecule 5.